Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.

Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA.

Clin Pharmacokinet. 2011 Jan;50(1):1-24. doi: 10.2165/11536640-000000000-00000. Review.

PMID:
21142265
2.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2007;46(1):13-58. Review.

PMID:
17201457
3.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2013 May;52(5):303-31. doi: 10.1007/s40262-013-0039-8. Review.

PMID:
23475567
4.

Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.

Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.

PMID:
19817503
5.

Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, Zhong MK, Lu WY.

Br J Clin Pharmacol. 2008 Jun;65(6):893-907. doi: 10.1111/j.1365-2125.2008.03109.x. Epub 2008 Feb 15.

6.

Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.

de Winter BC, Monchaud C, Prémaud A, Pison C, Kessler R, Reynaud-Gaubert M, Dromer C, Stern M, Guillemain R, Knoop C, Estenne M, Marquet P, Rousseau A.

Clin Pharmacokinet. 2012 Jan 1;51(1):29-39. doi: 10.2165/11594050-000000000-00000.

PMID:
22054177
7.

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.

J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

8.

How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2014 Mar;53(3):227-45. doi: 10.1007/s40262-013-0124-z. Review.

PMID:
24327238
9.

Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA.

Br J Clin Pharmacol. 2012 May;73(5):727-40. doi: 10.1111/j.1365-2125.2011.04140.x.

10.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.

PMID:
21190834
11.

[Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].

Jiao Z, Shen J, Zhong LJ, Yu YQ, Zhong MK.

Yao Xue Xue Bao. 2006 Mar;41(3):272-6. Chinese.

PMID:
16759002
12.

Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.

Dong M, Fukuda T, Cox S, de Vries MT, Hooper DK, Goebel J, Vinks AA.

Br J Clin Pharmacol. 2014 Nov;78(5):1102-12. doi: 10.1111/bcp.12426.

13.

Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.

Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P.

Clin Pharmacokinet. 2008;47(4):277-84.

PMID:
18336056
14.

Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Frymoyer A, Verotta D, Jacobson P, Long-Boyle J.

Br J Clin Pharmacol. 2013 Feb;75(2):463-75. doi: 10.1111/j.1365-2125.2012.04372.x.

15.

Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.

Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.

Kidney Int. 2014 Jun;85(6):1434-43. doi: 10.1038/ki.2013.517. Epub 2014 Jan 8.

PMID:
24402086
16.

Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.

Staatz CE, Tett SE.

Arch Toxicol. 2014 Jul;88(7):1351-89. doi: 10.1007/s00204-014-1247-1. Epub 2014 May 4. Review.

PMID:
24792322
17.
18.

Population pharmacokinetics of mycophenolic acid in renal transplant recipients.

van Hest RM, van Gelder T, Vulto AG, Mathot RA.

Clin Pharmacokinet. 2005;44(10):1083-96.

PMID:
16176120
19.

Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease.

de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA.

Ther Drug Monit. 2009 Jun;31(3):382-90. doi: 10.1097/FTD.0b013e3181a23f1a.

PMID:
19363460
20.
Items per page

Supplemental Content

Write to the Help Desk